Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459743 | 1.00 | GAA (0.72) | GAAALDH1A1POLBKMT2AMAPK1 | |
| SCHEMBL6452966 | 0.83 | NPC1 (0.78) | GAAALDH1A1POLBKMT2AMAPK1 | |
| SCHEMBL31722815 | 0.82 | ALDH1A1 (0.60) | GAAALDH1A1POLBMAPK1NPSR1 | |
| SCHEMBL6455841 | 0.78 | LMNA (0.74) | KMT2A | |
| SCHEMBL6455832 | 0.78 | LMNA (0.74) | KMT2A | |
| SCHEMBL13753555 | 0.78 | MEN1 (0.62) | GAAKMT2AMAPK1 | |
| SCHEMBL6787214 | 0.76 | CA2 (0.59) | — | |
| SCHEMBL6787220 | 0.76 | CA2 (0.59) | — | |
| SCHEMBL10200305 | 0.75 | NPC1 (0.67) | GAAALDH1A1POLBKMT2ANPSR1 | |
| SCHEMBL845157 | 0.75 | ALDH1A1 (0.57) | ALDH1A1KMT2AMAPK1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | POWERS GORDON D (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005039494-A2 | INHIBITORS OF RNASE P PROTEINS AS ANTIBACTERIAL COMPOUNDS | MESSAGE PHARMACEUTICALS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187409-A1 | Inhibitors of RNase P proteins as antibacterial compounds | RNASEH1, RNASEL, RNASE1 | GAA 118/4885ALDH1A1 2005/4885POLB 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.